Management of children with infantile hemangioma treated by systemic propranolol

Česká verze

Authors: J. Mališ ¹; A. Mišove ¹; S. Zimová ¹; K. Bláhová ²; V. Stará ²; N. Krejčová ²; M. Kynčl ³; M. Dvořáková ³; B. Prosová ³; M. Šimsová ⁴; R. Katra ⁵; A. Sukop ⁶
Authors place of work: Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha ¹; Pediatrická klinika 2. LF UK a FN Motol, Praha ²; Klinika zobrazovacích metod 2. LF UK a FN Motol, Praha ³; Klinika dětské chirurgie 2. LF UK a FN Motol, Praha ⁴; Klinika ušní, nosní a krční 2. LF UK a FN Motol, Praha ⁵; Klinika plastické chirurgie 3. LF UK a FN Královské Vinohrady, Praha ⁶
Published in the journal: Čes-slov Pediat 2020; 75 (5): 285-291.
Category: Přehledový článek

Summary

Infantile hemangioma (IH) occurs in 5 to 10% of children under one year of age. This benign vascular tumor is characterized by three phases of growth –⁠ proliferation, plateau and involution. Modern non-selective β-blocker systemic therapy (propranolol) offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.

Keywords:

infantile hemangioma – propranolol

Zdroje

1. Kilcline C. Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25 (2): 168–173.

2. Léauté-Labrèze C. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities. J Eur Acad Dermatol Venereol 2011; 25 (11): 1245–1253.

3. Baselga E. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatol 2016; 152 (11): 1239–1243.

4. Léauté-Labrèze C. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372 (8): 735–746.

5. Mališ J, Faberová R, Bučková H, et al. Současné terapeutické možnosti u infantilních hemangiomů. Čes-slov Dermatol 2017; 92 (2): 103–108. ISSN: 0009-0514.

6. Léauté-Labrèze C, Baselga Torres E, et al. The infantile hemangioma referral score: A validated tool for physicians. Pediatrics 2020 Apr; 145 (4): e20191628. doi: 10.1542/peds.2019-1628.

7. Léauté-Labrèze C. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358 (24): 2649–2651.

8. Vredenborg AD. Multiple cutaneous infantile haemangiomas and the risk of internal haemangioma. Br J Dermatol 2013; 169 (1): 188–191.

9. Chang L, Lv D, Yu Z, et al. Infantile hemangioma: factors causing recurrence after propranolol treatment. Pediatr Res 2018; 83 : 175–182.

10. Bagazgoitia L, Hernandez-Martin A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol 2011; 28 : 658–662.

11. Mališ J, Stará V, Bláhová K, et al. Infantilní hemangiomy. Současné léčebné postupy. Čes-slov Pediat 2017; 72 (4): 245–254. ISSN: 0069-2328; 1805-4501